

Consumer Update

July 2023

Tofacitinib sodium succinate -Risk of Hypoglycemia & Retinal venous thrombosis

EDA performs label update to include the following:

Special warnings and precautions for use
Hypoglycaemia in patients treated for diabetes

There have been reports of hypoglycaemia following initiation of tofacitinib in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycaemia occurs.

Retinal venous thrombosis

Retinal venous thrombosis (RVT) has been reported in patients treated with tofacitinib. The patients should be advised to promptly seek medical care in case they experience symptoms suggestive of RVT.

CLINICAL PARTICULARS

Therapeutic indication
Rheumatoid arthritis

Psoriatic arthritis
Ankylosing spondylitis
Ulcerative colitis
Juvenile idiopathic arthritis (JIA)

References: HPRA (Click here)